Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
November 18, 2015
RegMed’s close: seized the upside but, where is the line in the sand of support?
November 16, 2015
RegMed’s close: a day of anything goes and it did, then the sector ended neutral
November 16, 2015
Regenerative Medicine Earnings Scorecard - Q3/2015
November 12, 2015
RegMed’s close: sector skids on financial results and unconvincing expectation in development platforms
November 8, 2015
RegMed’s close: down, down, up and up as tail and head winds compete, check your landing instructions
November 5, 2015
RegMed’s close: as the sector balloon deflates, BLUE takes a BIG hit joined by JUNO, ONCE, QURE and KITE
November 5, 2015
RegMed’s mid-day: support breaks down
November 4, 2015
RegMed’s close: retreating, reversing and reverting to maintain gains
November 2, 2015
RegMed’s close: another wild swing, a short-term feeding frenzy?
October 31, 2015
RegMed’s close: good-bye October, the transition month had the sector testing and retesting lows
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.